Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Institute of Hematology & Blood Diseases Hospital, China: Clinical Trials & FDA Approval Profile

Institute of Hematology & Blood Diseases Hospital, China (Global / Institutional) sponsors 191 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 142 active protocols (86 recruiting now), 12 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)4.7%
Median Closed Enrollment vs National (145 pts)41 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Institute of Hematology & Blood Diseases Hospital, China
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)191
Active Pipeline (Recruiting Now)142 (86)
Completed vs Stopped Early12 / 9 (4.7%)
Median Closed Actual Enrollment41 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Institute of Hematology & Blood Diseases Hospital, China
Hospital Research SiteLocationShared Protocols
Nanfang Hospital, Southern Medical UniversityGuangzhou6

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Institute of Hematology & Blood Diseases Hospital, China
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06882057Newly-diagnosed Low Risk Pediatric B-cell ALL ProtocolPhase II/IIIRECRUITING
NCT06855810Newly-diagnosed Pediatric T-cell ALL ProtocolPhase II/IIIRECRUITING
NCT06764238Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolPhase II/IIIRECRUITING
NCT07152041Newly-diagnosed Pediatric Ph-positive B-ALL ProtocolPhase IIIRECRUITING
NCT07441993Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZLPhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Institute of Hematology & Blood Diseases Hospital, China Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI